NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
The upcoming portfolio of respiratory products aims to provide effective solutions for a range of respiratory conditions
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
The facility is over 79,000 square feet and is equipped with packaging lines
The increase of stake in Aster DM Healthcare is a reiteration of the confidence in the business across geographies
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
Subscribe To Our Newsletter & Stay Updated
